Nexalin Technology Publishes Study on Treating Gambling Disorder and Alcohol Use Disorder.

Nexalin Technology announced the publication of a peer-reviewed study in The American Journal on Addictions. The study evaluated the safety and efficacy of Nexalin's 15 milliamp neurostimulation device in a patient diagnosed with both gambling disorder and alcohol use disorder. The patient achieved complete abstinence from both after 20 outpatient treatment sessions over 10 days, with marked improvement in cognitive control and no adverse effects during a three-month follow-up period. The authors conclude that Nexalin's device is a safe and efficacious potential treatment for GD-AUD comorbidity.